| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
EVP, Chief Financial Officer | Chief Financial Officer
2 companies
Dulac Edward J III is an EVP, Chief Financial Officer at NTLA, with reported holdings spanning 2 companies. Recent filings cover 0 purchases and 20 sales. Those positions are worth an estimated $2.1M at current prices.
Our model assigns Dulac Edward J III a strong insider score of 81/100, based on 15 past trades. Over a 12-month horizon, 92.3% of those trades were profitable, with an average 12-month return of +56.4%.
Dulac Edward J III's largest disclosed position is in NTLA as EVP, Chief Financial Officer, worth about $1.8M. The recent filings there lean toward selling, a net 21,952 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 10, 2023 | FATE Fate Therapeutics Inc | Chief Financial Officer | Sell | 7,331 | $5.24 | $38,414.44 | -5.4% | -0.2% | -16.8% | |
| Aug 18, 2022 | FATE Fate Therapeutics Inc | Chief Financial Officer | Sell | 5,135 | $29.81 | $153,051.37 | -1.8% | -32.0% | -90.8% | |
| Jan 11, 2022 | FATE Fate Therapeutics Inc | Chief Financial Officer | Sell | 1,770 | $48.45 | $85,757.40 | -0.8% | -24.6% | -88.0% | |
| Dec 20, 2021 | FATE Fate Therapeutics Inc | Chief Financial Officer | Sale+OE | 15,977 | $60.00 | $958,620.00 | -12.6% | -37.3% | -79.0% | |
| Sep 28, 2021 | FATE Fate Therapeutics Inc | Chief Financial Officer | Sale+OE | 19,460 | $62.53 | $1,216,833.80 | -27.1% | -4.8% | -62.0% | |
| Aug 19, 2021 | FATE Fate Therapeutics Inc | Chief Financial Officer | Sell | 3,474 | $88.26 | $306,602.40 | -2.1% | -37.5% | -66.1% |